Takeda Pharma (TKPYY) 24.0500 $TKPYY The Global Vaccine

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Takeda Pharma (TKPYY) 24.0500 $TKPYY

The Global Vaccine Market Forecast is Expected to Grow at a CAGR of around 12% during 2012-2017
M2 - Fri Mar 28, 10:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/87zbl9/global_vaccine) has announced the addition of the "Global Vaccine Market Forecast to 2017" report to their offering. Of late, the vaccines market is burgeoning with immense activities. Big pharmaceutical companies like GSK, Pfizer, Merck etc. are struggling to maintain their revenue and operating incomes amidst patent cliffs of blockbuster drugs. In such a scenario, vaccines, which have high entry barriers for generic players and the potential to generate blockbuster sales, are increasingly alluring the players. Besides, the market has also gained momentum due to the recent technological advances that now allow the manufacturing of high efficacy combination vaccines, providing protection from a plethora of diseases in one schedule. This has resulted in the introduction of several promising vaccines, actively promoted by health agencies and non-profit organizations to offer maximum immunization coverage, especially in the developing regions with high incidence rates of infectious diseases. In the report, the vaccine market has been studied on three distinct levels: Regional, Therapeutic Category, and Company. For regional analysis, key vaccine markets that together constitute around 90% of the global market, have been profiled. Further, the market has been broken down into 16 distinct therapeutic categories and their current and future outlook to 2017 has been analyzed. Through this, our analysts have conducted a thorough opportunity assessment in various therapeutic categories and regions to clearly highlight avenues which offer maximum opportunities for growth. Companies Mentioned: - AstraZeneca Plc. - Baxter International Inc. - BioCSL (CSL Biotherapies) - Crucell - Dendreon Corporation - Emergent Biosolutions - GSK - Merck - Novartis - Pfizer - Sanofi-Pasteur - Takeda Pharmaceutical Company Limited For more information visit http://www.researchandmarkets.com/research/87...al_vaccine About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Analyzing the Global Diabetes Market 2014
M2 - Thu Mar 27, 9:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/824dx5/analyzing_the) has announced the addition of the "Analyzing the Global Diabetes Market" report to their offering. Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well. Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters. Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Currently, the US remains the single largest source of product revenues in diabetes management, at roughly 37% of the global market, but that percentage is expected to drop to 28% by 2018, primarily as a result of significant growth in the Asia-Pacific region. Key Topics Covered: A. Executive Summary B. Introduction to Diabetes C. Global Diabetes Market D. Market for Insulin E. Analysis of Novel Emerging Drug Classes for Diabetes Treatment F. Analysis of Key Molecules G. Industry Research & Development H. Diabetes Market in India I. Diabetes Market in China J. Competition in the Industry K. Leading Industry Contributors L. Global Diabetes Market: Future Perspective M. Glossary of Terms Companies Mentioned - Takeda Pharmaceutical Company - Sanofi SA - Novo Nordisk - Merck & Co. - Eli Lilly & Co. For more information visit http://www.researchandmarkets.com/research/82...lyzing_the

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session
PR Newswire Europe - Thu Mar 27, 7:02AM CDT
-- Sub-analyses Investigate the Effects of alogliptin on Cardiovascular Mortality Rates and Hospitalization for Heart Failure in Type 2 Diabetes Patients with Recent Acute Coronary Syndrome

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014
M2 - Fri Mar 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tp6b8p/diffuse_large) has announced the addition of the Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 report to their offering. Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014 Summary Our clinical trial report, Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Diffuse Large B-Cell Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diffuse Large B-Cell Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Key Topics Covered: Table of Contents Table of Contents List of Tables List of Figures Introduction Diffuse Large B-Cell Lymphoma Report Guidance Clinical Trials by Region Clinical Trials and Average Enrollment by Country Top Five Countries Contributing to Clinical Trials in Asia-Pacific Top Five Countries Contributing to Clinical Trials in Europe Top Countries Contributing to Clinical Trials in North America Top Five Countries Contributing to Clinical Trials in Middle East and Africa Top Five Countries Contributing to Clinical Trials in Central and South America Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in G7 Countries Clinical Trials in G7 Countries by Trial Status Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials Clinical Trials by Phase in E7 Countries Clinical Trials in E7 Countries by Trial Status Clinical Trials by Phase In Progress Trials by Phase Clinical Trials by Trial Status Clinical Trials by End Point Status Unaccomplished Trials of Diffuse Large B-Cell Lymphoma Subjects Recruited Over a Period of Time Clinical Trials by Sponsor Type Prominent Sponsors Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Prominent Drugs Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma Dec 09, 2013: Senesco Announces Results of Cohort 3 in SNS01-T Phase 1b/2a Trial Aug 15, 2013: Seattle Genetics Announces Initiation of Phase 2 Trial of ADCETRIS in Combination with Current Standard of Care for Frontline Diffuse Large B-Cell Lymphoma Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma Jun 10, 2013: Immunomedics's 90Y-Epratuzumab Study Shows Improvement Of Therapy Results Following R-CHOP In Patients With Diffuse Large B-Cell Lymphoma May 10, 2013: Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint In Diffuse Large B-Cell Lymphoma Clinical Trial Profiles Clinical Trial Overview of Top Companies F. Hoffmann-La Roche Ltd. Clinical Trial Overview of F. Hoffmann-La Roche Ltd. Celgene Corporation Clinical Trial Overview of Celgene Corporation Amgen Inc. Clinical Trial Overview of Amgen Inc. Novartis AG Clinical Trial Overview of Novartis AG Takeda Pharmaceutical Company Limited Clinical Trial Overview of Takeda Pharmaceutical Company Limited Pharmacyclics, Inc. Clinical Trial Overview of Pharmacyclics, Inc. GlaxoSmithKline plc Clinical Trial Overview of GlaxoSmithKline plc Bayer AG Clinical Trial Overview of Bayer AG AstraZeneca PLC Clinical Trial Overview of AstraZeneca PLC Immunomedics, Inc. Clinical Trial Overview of Immunomedics, Inc. Clinical Trial Overview of Top Institutes / Government National Cancer Institute Clinical Trial Overview of National Cancer Institute Fred Hutchinson Cancer Research Center Clinical Trial Overview of Fred Hutchinson Cancer Research Center Groupe d'Etudes de Lymphomes de L'Adulte Clinical Trial Overview of Groupe d'Etudes de Lymphomes de L'Adulte Mayo Clinic Clinical Trial Overview of Mayo Clinic The University of Texas M. D. Anderson Cancer Center Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center FUDAN University Clinical Trial Overview of FUDAN University Memorial Sloan Kettering Cancer Center Clinical Trial Overview of Memorial Sloan Kettering Cancer Center The Lymphoma Academic Research Organisation Clinical Trial Overview of The Lymphoma Academic Research Organisation Massachusetts General Hospital Clinical Trial Overview of Massachusetts General Hospital Stanford University Clinical Trial Overview of Stanford University Five Key Clinical Profiles Appendix Abbreviations Definitions Research Methodology Secondary Research About Us Contact Us Disclaimer Source List of Tables Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Suspended Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Withdrawn Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Terminated Clinical Trials, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pharmacyclics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Immunomedics, Inc., 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Groupe d'Etudes de Lymphomes de L'Adulte, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by FUDAN University, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by The Lymphoma Academic Research Organisation, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014- List of Figures Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2014- Therapeutics, Global, Clinical Trials In Progress by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014- GlobalData Methodology For more information visit http://www.researchandmarkets.com/research/tp...fuse_large About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Takeda Receives Positive CHMP Opinion for Entyvio(R) (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease
PR Newswire Europe - Fri Mar 21, 7:40AM CDT
Takeda Pharmaceutical Company Limited ("Takeda") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive Opinion for Entyvio(R) (vedolizumab), a humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis (UC) and adults with moderately to severely active Crohn's disease (CD) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF-alpha) antagonist. UC and CD are the two most common types of inflammatory bowel disease (IBD), affecting more than four million people worldwide, including approximately 2.2 million Europeans.

PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Update from Celgene - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:30AM CDT
Celgene will leave no stone untuxirned to increase the awareness and understanding regarding pancreatic cancer in Europe.

Sucampo's NDA Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 4:05PM CDT
Sucampo Pharma recently announced that its New Drug Application (NDA) for the liquid formulation of Amitiza will not be filed in the second half of 2014.

Takeda Appoints Giles Platford Head of Emerging Markets
PR Newswire Europe - Tue Mar 18, 4:02AM CDT
ZURICH, March 18, 2014 /PRNewswire/ --

Regulatory Setback for Sucampo in the U.K. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:40AM CDT
Sucampo's type II variation of Amitiza refused approval for opioid- induced constipation (OIC) in the U.K.

Narrower Loss at Orexigen in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:30AM CDT
Orexigen Therapeutics reported a net loss of 21 cents per share in the fourth quarter of 2013.

Orexigen Therapeutics Reduces Q4 Loss by 34%
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 12, 4:27PM CDT
Fat-fighting clinical-stage biopharmaceutical company Orexigen Therapeutics posted a narrower fourth-quarter loss on the back of lower research and development expenses. For the quarter, Orexigen recorded $857,000 in revenue which is...

Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...

The Zacks Analyst Blog Highlights:Actavis, Sanofi, Takeda Pharmaceutical, Forest Laboratories and Iconix Brand Group
PR Newswire - Tue Mar 04, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Actavis, Inc. (NYSE:ACT-Free Report), Sanofi (NYSE:SNY-Free Report), Takeda Pharmaceutical Company Limited (OTC:TKPYY-Free Report), Forest Laboratories Inc. (NYSE:FRX-Free Report) and Iconix Brand Group Inc. (Nasdaq:ICON-Free Report).

Concise Analysis of the Future Prospects of Global Personalized Medicine Market
M2 - Tue Mar 04, 5:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/zpctsr/future_prospects) has announced the addition of the "Concise Analysis of the Future Prospects of Global Personalized Medicine Market" report to their offering. Over the years, the Global Personalized Medicine market has been witnessing the emergence of various tools and technologies from the reputed vendors. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Further, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 for predicting the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Geographical Segmentation 8. Key Leading Countries 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 17. Other Reports in this Series Companies Mentioned: - Abbott Laboratories - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Co. - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Danaher Corp. - Eli Lilly and Co. - Evotec AG - F. Hoffmann-La Roche Ltd. - GE Healthcare Ltd. - Genelex Corp. - GlaxoSmithKline plc - Hologic Inc. - Johnson & Johnson - Laboratory Corporation of America Holdings - Life Technologies Corp. - Merck KGaA - Mitsubishi Tanabe Pharma Corp. - Myriad Genetics Inc. - Novartis AG - Novartis AG - PerkinElmer Inc. - Pfizer Inc. - Pfizer Inc. - Quest Diagnostics Inc. - Sanofi S.A. - Sanofi S.A. - Siemens Healthcare - Sigma-Aldrich Corp. - Takeda Pharmaceutical Co. Ltd. - Teva Pharmaceutical Industries Ltd. - Thermo Fisher Scientific Inc. - Transgenomic Inc. For more information visit http://www.researchandmarkets.com/research/zp..._prospects

Actavis Challenges Patents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 3:45PM CST
Actavis announced that it is seeking FDA approval for its generic versions of Multaq and Colcrys.

Sucampo Gains On Better-Than-Expected Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 1:20PM CST
Shares of Sucampo Pharmaceuticals gained 11.9% following the release of fourth quarter results on Feb 26, 2014.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 111

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 36

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 358

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 26

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 288

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 438

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 395

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
rshangout.com/blog/news?page=2">More News Articles